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Objective: Minimally invasive mitral valve repair may be associated with prolonged 
cardioplegic arrest times and ischemic reperfusion injury. Intravenous (propofol) and volatile 
(sevoflurane) anesthesia are routinely used during cardiac surgery and are thought to provide 
cardioprotection; however, the individual contribution of each regimen to cardioprotection is 
unknown. Thereby we sought to compare the cardioprotective effects of propofol and 
sevoflurane anesthesia in patients undergoing minimally invasive mitral valve repair. 
Design: A single-center single blind randomized controlled trial. 
Setting: A specialized regional cardiac surgery center in Italy. 
Participant: The study enrolled 62 adults undergoing elective isolated minimally invasive 
mitral valve repair for degenerative disease. Exclusion criteria included secondary mitral 
regurgitation, previously treated coronary artery disease, diabetes mellitus, chronic renal 
failure requiring dialysis, atrial fibrillation, and documented allergy to either propofol or 
sevoflurane. 
Intervention: All patients received video-assisted right minimally invasive minithoracotomy. 
Patients were randomized to receive propofol or sevoflurane anesthesia in a 1:1 ratio. 
Measurements and main results: Cardiac troponin I release was measured over the first 72 
h postoperatively. Operative, cross clamp, and total bypass times were similar between 
groups. Cardiac troponin I release was non-significantly reduced in the propofol group (p = 
0.62) and peak troponin I release was correlated with cross clamp time in both groups. There 
were no differences in terms of intraoperative lactate release and blood pH in between 
groups. 
Conclusions: Propofol and sevoflurane anesthesia were associated with similar degrees of 
myocardial injury, indicating comparable cardioprotection. Myocardial injury was directly 
related to the duration of cardioplegic arrest. 
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Introduction 
The magnitude of cardiac damage resultant from ischemic-reperfusion injury during cardiac 
surgery is inversely related to both early and long-term survival.1 Accordingly, there is 
significant interest in reducing ischemic-reperfusion injury to improve postoperative 
outcomes. To this end, both sevoflurane and propofol have demonstrated utility for pre-
operative conditioning.2-4 Sevoflurane is thought to reduce reperfusion injury by attenuating 
cellular Ca2+ overload,5 whereas propofol exerts antioxidant effects that decrease oxidative 
myocardial injury secondary to the generation of reactive oxygen species.6 Yet, it is unclear 
whether one of these agents is superior for preventing damage during cardiac surgery.7 
A majority of previous studies examining the protective conditioning effects of sevoflurane 
and propofol were conducted in heterogeneous populations (e.g., different baseline cardiac 
diseases, different operative techniques) with several confounding morbidities (e.g. inclusion 
of patients with diabetes or previous ischemic episodes).8 Patients with organic mitral 
regurgitation in the absence of coronary disease may represent an ideal substratum for 
investigating the utility of potential conditioning agents. Moreover, minimally invasive mitral 
valve repair is a procedure associated with prolonged durations of ischemia9 and significant 
ischemic-reperfusion injury, such that strategies for decreasing troponin release in this 
context are needed.  
The aim of this study was to determine whether propofol or sevoflurane anesthesia confers 
superior cardioprotection in patients undergoing isolated minimally invasive mitral valve 
repair.  
 
Methods 
Ethical approval 
This trial was registered with ClinicalTrials.gov (NCT02551328). The study protocol was 
approved by the Area Vasta Toscana Ethics Committee (reference CEAVNO no. 452/14) and 
conducted in accordance with the Declaration of Helsinki. All patients provided written 
informed consent prior to study participation. All authors had access to the study data and 
reviewed and approved the final manuscript. 
 
Trial design  
The MINI-SEVO trial was a single-center, single blind, randomized controlled trial. 
Participants were randomly allocated to propofol or sevoflurane anesthetic conditioning 
regimens using a 1:1 ratio.  
 
Participants 
Adults (age >18 years) undergoing elective isolated minimally invasive mitral valve repair 
for degenerative disease were eligible for study participation. The exclusion criteria were 
secondary mitral regurgitation, previously treated coronary artery disease such as a history of 
coronary stenting or coronary artery bypass grafting, diabetes mellitus, chronic renal failure 
requiring dialysis, atrial fibrillation (AF), or documented allergy to either propofol or 
sevoflurane. The study was conducted at G. Pasquinucci Heart Hospital, Fondazione Toscana 
G. Monasterio, a specialized regional cardiac surgery center in Italy.  
 
Intervention 
Beta-adrenergic antagonists and other relevant medications were continued until the morning 
of surgery in all patients. In the operating room, patients were monitored with 5-lead 
electrocardiography, left radial artery catheter, capnography, pulse oximetry, blood findings, 
and rectal/urine bladder temperatures. Transesophageal echocardiography was used in all 
patients.  
In the group randomized to sevoflurane (Sevoflurane®, Abbott), anesthesia was induced with 
intravenous sufentanil (0.5–1 mcg kg -1; Hameln Pharmaceuticals, Hameln, Germany) and 
midazolam (0.08–0.2 mg kg -1; Mayrhofer Pharmazeutika, Linz, Austria). Tracheal intubation 
was facilitated with intravenous rocuronium (0.6–1 mg kg -1; Pharmadox Healthcare, Malta). 
Anesthesia was maintained with sevoflurane at a minimum end-tidal concentration of at least 
1 minimal alveolar concentration (MAC) throughout the entire procedure, including 
cardiopulmonary bypass (CPB) and endovenous sufentanil (0.01–0.02 mcg kg -1 min). During 
CPB, sevoflurane was administered in the oxygenator circuit through a calibrated vaporizer 
and MAC was measured at the outlet of the oxygenator of the extracorporeal circulation. 
Patients of this group received no propofol: neither during surgery, nor during ICU stay. 
In the group randomized to propofol (Diprivan, Astra-Zeneca, Stockholm, Sweden), 
anesthesia was induced with intravenous sufentanil (0.5–1 mcg kg -1) and propofol  (2 mg- kg 
-1). Tracheal intubation was facilitated with intravenous rocuronium (0.6–1 mg kg -1). 
Anesthesia was maintained with propofol (0.1 -0.5 mg kg -1 min) and sufentanil (0.01–0.02 
mcg kg -1 min). No volatile anesthetic was used at any time during the procedure.  
In both groups, depth of anesthesia was monitored with bispectral index (BIS XP ®, Aspect 
Medical System, Newton, MA); the dosage of propofol and sevoflurane (within the above 
ranges) was titrated to maintain BIS values from 40 to 60. 
Postoperatively, the inspired oxygen fraction was set at 0.5 and the positive end expiratory 
pressure at 5 cm H20. Sedation in ICU was continued for 3-4 hours, propofol in the propofol 
group and boluses of midazolam if required in the sevoflurane group. After 3-4 hours, if 
partial pressure of oxygen/fraction of inspired oxygen was above 200, PaCo2 between 35-45 
mmHg and bleeding from chest tubes was < 1 mL/kg, sedation was stopped.  
Extubation was then performed if patients’ cardio-circulatory, respiratory (partial pressure of 
oxygen/FiO2 < 250, respiratory rate > 25/min, FiO2 40-50%) and neurological criteria were 
within range. Criteria for intensive care discharge were: hemodynamic stability with no 
inotropic support, spontaneous breathing and clear neurological status.   
 
Surgical technique 
The surgical approach used in this study has been previously described.10 Briefly, a central 
aortic cannulation was performed and venous drainage was achieved by percutaneous 
cannulation of the right femoral vein. A small 5-cm incision was made at the level of the 4th 
intercostal space. Two ports were used for camera insertion, cardiotomy venting, CO2 
insufflation, and other pericardial stay sutures. After CPB, the aorta was clamped under direct 
supervision and cold crystalloid cardioplegia (CUSTODIOL® Bretschneider’s HTK-
Solution, DR. FRANZ KÖHLER CHEMIE, Bensheim, Germany) with single antegrade 
delivery (25 ml kg -1) was used. The mitral valve was then exposed through a left para-septal 
atriotomy. Mitral repair was performed in accordance with the mechanism of regurgitation. 
 
Outcomes 
The primary outcome was myocardial injury as assessed by serum cardiac troponin I (cTnI) 
in blood samples collected preoperatively and at 1, 6, 12, 24, and 72 h after the end of the 
ischemic period. The institutional laboratory quantified cTnI by immunoassay (Cobas 6000 
analyzer series, Roche Diagnostic USA). Secondary outcomes were systemic metabolic stress 
as assessed by blood pH, lactate, and serum creatinine level; mechanical ventilation time; 
length of intensive care unit/high dependency unit stay; and left ventricular function. Blood 
samples for measuring lactate and pH were taken before CPB, during CPB (at 20 and 40 
min), and at the end of surgery. Blood samples for measuring serum creatinine were taken at 
6, 24, 48, and 72 h after surgery. Left ventricular function was assessed preoperatively and 
between days 4 and 6 postoperatively. Examinations were performed using the Philips 
Healthcare IE33 echocardiography system, and the biplane method of disks summation 
(modified Simpson’s rule) was applied to quantify left ventricular function. 
 
Sample size 
Cardiac troponin was measured the day before surgery (baseline) and 6 times after exposure 
to the anesthetic conditioning stimulus; considering an average pre-post correlation of 0.3 and 
an average post-post correlation of 0.5, we calculated a sample size of 60 (30 patients in each 
group).11 With analyses of variance and covariance, this sample size provided 90% power to 
detect a standardized difference in serum markers of 0.43 between groups providing there 
was no interaction between group and pathology. If there was an interaction, a sample size of 
60 had 80% power to detect a standardized difference in serum markers of 0.55 between 
groups. 
 
Randomization and blinding 
Random allocations were generated by computer software. Treatment allocations were (a) 
blocked with varying block sizes to ensure approximate balance in the number of participants 
allocated to each group; (b) generated prior to the study; and (c) accessed using a secure, 
internet-based randomization system to guarantee concealment until each participant’s 
identity and eligibility was confirmed and securely documented. A designated research nurse 
who was not involved in data collection performed patient randomization after acquiring 
written consent and as close as possible to the operation date. Participants were blinded to the 
intervention given that all conditioning was performed in the operatory theatre and there were 
no visible signs of the anesthetic conditioning regimens. Operating staffs were not blinded to 
treatment given the nature of the study. 
 
Statistical analysis 
The assumption of normality of each variable distribution was tested with the Shapiro–
Wilk test. Normally distributed variables are reported as the mean ± standard deviation 
or median and interquartile range (IQR). Categorical variables are reported as the 
percentage. Continuous outcomes are summarized and presented graphically as 
geometric means and standard errors; a natural logarithmic transformation was applied 
to the data to normalize distributions. Categorical data are summarized as the number 
(percentage). cTnI and other markers were analyzed by fitting multilevel mixed effect 
linear regression models (continuous variable measured at different time points). 
Model validity was checked and poor fit was addressed by exploring transformations. 
Outcomes analyzed on a logarithmic scale were transformed back to the original scale 
after the analysis and results were presented as geometric mean ratios (GMRs). 
Likelihood ratio tests were used to determine statistical significance. The effect of cross 
clamp time on cTnI release was explored with a Pearson’s correlation analysis. No sub-
group analyses were planned. The trial was not powered to detect differences in clinical 
outcomes; therefore, frequencies are tabulated descriptively. The threshold for 
statistical significance was p < 0.05. All analyses were performed using R-project (R 
Core Team 2013, Vienna, Austria; http://www.R-project.org/) (packages: ‘stat’, ‘graph’, 
‘ggplot2’).  
 
Results 
Patient recruitment 
Between March 2015 and December 2016, 225 patients were assessed for study inclusion; of 
these, 160 did not meet the inclusion/exclusion criteria and were excluded (see CONSORT 
diagram / figure 1. After randomization, 3 patients were excluded due to concomitant 
tricuspid surgery and AF ablation. There were 2 protocol violations: 1 patient allocated to the 
propofol group received sevoflurane and 1 patient allocated to the sevoflurane group received 
propofol. One patient in the sevoflurane group was converted to stenotomy and underwent 
mitral valve replacement for a failed repair. These patients were included in the intention-to-
treat population. Therefore, 62 participants were included in the per-protocol analysis (Figure 
1). 
 
Baseline data 
The mean age of the population was 64.7 ± 11.9 years and 28 of 62 patients (45.1%) were 
male. Patients allocated to propofol group were older than those allocated to the sevoflurane 
group (68.3 ± 9.5 years vs. 60.7 ± 12.5 years, respectively). The median Logistic European 
System for Cardiac Operative Risk Evaluation score was 3.7 (IQR, 5). Other baseline 
characteristics and mitral valve regurgitation values are summarized in Table 1.  
 
Operative data 
Total CPB times and cross clamp times were similar between the propofol and sevoflurane 
groups (CPB: 139.7 ± 40.5 min vs. 141.2 ± 38.7 min, cross clamp: 90.3 ± 31.5 min vs. 94.3 ± 
28.5 min, respectively). All patients received cold crystalloid antegrade cardioplegia. The 
average sevoflurane MAC was 1.2 ± 0.2. The average propofol infusion was 2.6 ± 0.7 mg -1 
kg -1. Except for 1 patient, mitral valve repair was successful in all cases with no residual 
regurgitation on intraoperative trans-esophageal echocardiography. The type of rings 
implanted and repair techniques used are summarized in Table 2. 
 
Postoperative outcomes 
Time courses of cTnI values are shown in Figure 2A. Preoperative concentrations of cTnI 
were undetectable in both treatment groups (< 0.01 ng ml -1). Concentrations of cTnI were 
increased postoperatively and peaked at 6 h after surgery; these values were, on average, 8% 
lower in the propofol group compared to the sevoflurane group, but this difference was not 
statistically significant (GMR 0.92; 95% confidence interval [CI] 0.63–1.27, p = 0.62). Peak 
cTnI release occurring at 6 and 12 h after surgery was positively correlated with cross clamp 
time in both groups (p < 0.001) (Fig. 3, 4). 
Postoperative blood pH, lactate, and serum creatinine were marginally lower in the 
sevoflurane group compared to the propofol group (blood pH: mean difference [MD] 0.02, 
95% CI −0.02–0.04, p = 0.19; lactate: GMR 1.12, 95% CI 0.92–1.23, p = 0.68; serum 
creatinine: GMR 1.13, 95% CI 1–1.19, p = 0.33) (Fig. 2B–D). Mechanical ventilation time 
was lower in the sevoflurane group compared to the propofol group (median 497 min [IQR, 
460] vs. 589 min [285], respectively; p < 0.05), while intensive care unit stay and total length 
of stay durations were similar between the propofol and sevoflurane groups (intensive care 
unit stay: mean 1186 ± 176 vs. 1215 ± 122 min); total length of stay: median 8 days (IQR, 3) 
vs. 8 days (IQR, 2)) (Table 3). Mean pre- and postoperative left ventricle ejection fractions 
were 58.2 ± 6.8% and 50 ± 5.7% in the propofol group and 59 ± 7.9% and 50 ± 10.3% in the 
sevoflurane group, respectively. 
  
Postoperative complications 
There were no in-hospital deaths. One patient in the sevoflurane group was re-operated for 
bleeding but conversion to sternotomy was not necessary. Other event rates were similar 
between the 2 treatment groups (Table 3). All patients were discharged with no or negligible 
residual mitral regurgitation. No unexpected serious adverse events occurred. 
 
Discussion 
To the best of our knowledge, this is the first study to compare the effects of propofol and 
sevoflurane as conditioning agents in patients undergoing isolated minimally invasive mitral 
valve repair. Our study found that both conditioning regimens were associated with similar 
degrees of myocardial injury. Bignami and colleagues compared propofol and sevoflurane in 
terms of cardiac troponin release in patients with coronary disease undergoing mitral 
surgery,12 and Landoni and colleagues investigated the effects of desflurane versus propofol 
in patients undergoing mitral surgery13; however, neither study clarified whether volatile 
anesthesia was superior to intravenous anesthesia for mitral valve repair. In the latter study, 
subjects with concomitant coronary disease were not excluded, and moreover desflurane was 
used only as preconditioning agent for 30 minutes. The vast majority of previous studies on 
anesthetic conditioning were conducted in the context of coronary bypass grafting, and very 
few investigations have focused on isolated valve repair.8 Additionally, investigations 
performed in patients with coronary disease failed to control for several confounding factors 
including diabetes and related medication use, previous angina, hibernating myocardium, 
coronary micro-embolization, no-reflow, and hypercholesterolemia.14 Accordingly, these 
studies have yielded inconsistent results.  
We believe that patients with isolated valve disease such as degenerative mitral valve disease 
provide an ideal scenario for testing the abilities of potential conditioning agents to prevent 
myocardial damage. Furthermore, organic mitral valve disease has a lower association with 
coronary disease than aortic valve disease, which is associated with hypertension, diabetes, 
and dyslipidemia.15 It can be argued that different forms of anesthetic conditioning (e.g., 
remote ischemic, volatile, etc.) do not add additional protection against cardioplegic arrest in 
the context of bypass grafting, since patients with coronary disease may already be naturally 
preconditioned. 
In the present study, we were unable to demonstrate superiority of one anesthetic regimen 
over another for decreasing cTnI release in patients who underwent isolated mitral valve 
repair; patients in the propofol group tended to have lower cTnI release, but this difference 
was not statistically significant. Moreover, postoperative left ventricular function assessed 
between days 4 and 6 was similar between the 2 treatment groups. Rather, we uncovered a 
positive correlation between cross clamp time and peak troponin release in both groups. 
Minimally invasive surgery may require longer operation times9 and thus an increased 
likelihood of ischemic-reperfusion injury in cardiac settings, accounting for an association 
between operation time and troponin release. 
With regard to secondary outcomes, mechanical ventilation time was significantly shorter in 
the sevoflurane group than in the propofol group. The duration of mechanical ventilation is 
influenced by the sedation regimen used in the intensive care unit; in this study, the 
suspension of continuous infusion of hypnotic agents before arrival in the intensive care unit 
in the sevoflurane group was likely the main cause of early extubation. 
An important strength of the present study was that we did not include patients with 
combined coronary disease, ensuring no previous exposure to angina or other natural 
ischemic preconditioning. Additionally, we excluded diabetic patients so as to avoid the 
possible influence of diabetic medication. This study was conducted in a high-volume mitral 
reference center with surgeons performing more than 50 mitral repairs per year, so that there 
was no learning curve effect on the present results. Finally, pain stimuli may elicit 
preconditioning as a confounding factor, such that the use of a minimally invasive procedure 
in this study reduced the contribution of nociceptive components.16  
This study had some limitations. First, this research was a proof-of-concept analysis that was 
primarily based on troponin release. For practical reasons, participants but not physicians and 
medical staff were blinded to treatment group assignments. Second, this trial did not include 
a third arm to examine synergy between sevoflurane and propofol, nor were the dose-
dependent effects of propofol and sevoflurane6 investigated; instead, our study design 
corresponded with routine anesthetic practice and evaluated potential differences between 2 
standard regimens. Third, our trial included relatively low-risk patients, which may limit its 
generalizability to larger patient populations. Notably, we did not follow-up patients in our 
study; however, only weak evidence supports the idea that anesthetic conditioning has effects 
on late post-surgical outcomes.8 Another important consideration is that in the propofol 
group, propofol infusion was continued in the intensive care unit and may have provided 
post-conditioning, whereas sevoflurane was not. There is some evidence that the 
preconditioning effect of sevoflurane is enhanced when treatment is maintained during the 
first 6 h after surgery,17 yet the most uniform cardioprotective effects are seen when 
sevoflurane is administered for the duration of the procedure.18 Finally, sufentanil was used 
in both groups; opioids produce cardioprotection against ischemia-reperfusion injury in 
rodents in a manner potentially related to adenosine receptor cross-talk.19 Future studies 
should address these important points in order to better inform the utility of different 
anesthetic preconditioning regimens in cardiac surgery. 
 
Conclusions 
Propofol and sevoflurane anesthesia were associated with similar degrees of myocardial 
injury in patients undergoing minimally invasive mitral valve repair for degenerative disease. 
Notably, injury was directly related to the duration of cardioplegic arrest regardless of the 
preconditioning regimen. 
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Figure legends 
Figure 1. Flow of patient enrolment. AF, atrial fibrillation; MIMVR, minimally invasive 
mitral valve repair; PIL, patient information leaflet. 
 Figure 2. Changes in blood parameters over time.  A. Cardiac troponin I. B: Lactate. C: 
Blood pH. C: Creatinine. Geometric means and 95% confidence intervals (CIs) are shown for 
different postoperative time points by group. Geometric mean ratios (GMRs) and 95% CIs 
for propofol versus sevoflurane are also shown. Data are expressed as the mean and standard 
deviation (SD) at each study time point by group and the mean difference (MD) and 95% CI 
for propofol versus sevoflurane. CPB, cardiopulmonary bypass. MV, mitral valve. There 
were no missing data.  
 
Figure 3. Correlation between cross clamp time and troponin I concentration at 6 h post-
surgery. Propofol (blue), adjusted R-squared value 0.43, correlation 0.67, p < 0.001; 
sevoflurane (red), adjusted R-squared value 0.34, correlation 0.6, p < 0.001.  
 
Figure 4. Correlation between cross clamp time and troponin I concentration at 12 h post-
surgery. Propofol (blue), adjusted R-squared value 0.35, correlation 0.61, p < 0.001; 
sevoflurane (red), adjusted R-squared value 0.34, correlation 0.61, p < 0.001.  
 
 
 
 
 
 
 
 
 
  
 
TABLE 1. Baseline characteristics  
 Randomized to 
propofol  
(n=31) 
Randomized to 
sevoflurane 
(n=31) 
p value Overall  
(N=62) 
   Age (year) 68.3±9.5 60.7±12.5 0.03 64.7±11.9 
   Male % 15 (48.3) 13 (41.9) 0.9 28 (45.1) 
   Body mass index 24.7±3.5 24.9±3.3 0.52 25.2±3.4 
   Creatinine (mg dl -1) 0.89±0.2 0.78±0.2 0.03 0.83±0.27 
   Logistic Euroscore 
(IQR) 
3.5 (4.1) 3.2 (4.3) 0.07 3.7(5) 
   Smoker/Ex smoker (%) 1 (3.2) 1 (3.2) - 2 (3.2) 
   Hypercholesterolemia 
(%) 
4 (12.9) 6 (19.3) 0.8 10 (16.1) 
   Family history for CV 
disease (%) 
6 (19.3) 4 (12.9) 0.8 10 (16.1) 
   Systemic Hypertension 
(%) 
8 (25.8) 6 (19.3) 0.85 12 (19.3) 
   Previous Stroke/TIA 
(%) 
1 (3.2) 0 1 1 (1.6) 
   Pulmonary 
Hypertension (%) 
3 (9.6) 4 (12.9) 1 7 (11.2) 
   LV function <50% (%) 3 (9.6) 4 (12.9) 1 7 (11.2) 
   LV function >50% (%) 28 (90.3) 27 (87) 1 55 (88.8) 
   NYHA I-II (%)  25 (80.6) 27 (87) 0.98 52 (83.9) 
   NYHA III (%) 6 (19.3) 4 (12.9) 0.8 10 (16.1) 
Degenerative mitral 
regurgitation  
    
Isolated posterior (%) 20 (64.5) 18 (58) 0.96 38 (61.3) 
   Isolated anterior (%) 5 (16.1) 4 (12.9) 1 9 (14.5) 
   Anterior and posterior 
(%) 
6 (19.3) 8 (25.8) 0.85 14 (22.5) 
Values are presented as median (interquartile range), mean ± standard deviation, or n (%). There were no 
missing data. CV, cardio vascular; LV, left ventricle; NYHA, New York Heart Association classification; 
TIA, transient ischemic attack. 
 
 
 
 
 
 
 
 TABLE 2. Intraoperative details 
 Randomized to 
propofol  
(n=31) 
Randomized to 
sevoflurane 
(n=31) 
p-value Overall  
(N=62) 
Operation time (min)  320±50.6 322±41 0.88 321.1±45.5 
Cross clamp time (min) 90.3±31.5 94.3±28.5 0.33 92.6±29.5 
Bypass time (min) 139.7±40.5 141.2±38.7 0.55 140±39 
Conversion to sternotomy 
(%) 
0 1 (3.2) 1 1 (1.6) 
Mitral repair techniques*♮     
   Resection (%) 16 (51.6) 14 (45.2) 0.93 30 (48.3) 
   Neochord (%) 15 (48.3) 24 (77.4) 0.34 39 (62.9) 
   Sliding (%) 4 (12.9) 7 (22.5) 0.61 11 (17.7) 
   Other (%) 2 (6.4) 2 (6.4) 1 4 (6.4) 
   CE-Physio II ring (%) 11 (35.4) 15 (48.3) 0.67 26 (41.9) 
   Sorin Memo 3D ring (%) 20 (64.5) 16 (51.6) 0.74 36 (58) 
Values are presented as median (interquartile range), mean ± standard deviation, or n (%). There were no 
missing data. * Patients may have more than one techniques.♮ One patient had mitral valve replacement 
with mechanical prosthesis.  
 
TABLE 3. Postoperative details 
 Randomized to 
propofol  
(n=31) 
Randomized to 
sevoflurane 
(n=31) 
p value Overall  
(N=62) 
Mechanical ventilation time 
(min) (IQR) 
589(285) 497(460) 0.05 572 (367) 
LOS ICU (min) 1186±176 1215±122 0.19 1200±120 
LOS total (day) (IQR) 8 (3) 8 (2) 1 8 (2) 
N of patients requiring 
inotrops/vasoconstrictors (%) 
12 (38.7) 11 (35.4) 1 23 (37) 
N of patients transfused (%) 3 (9.6) 5 (16.1) 0.77 8 (12.9) 
In hospital death (%) 0 0 - 0 
De novo Atrial Fibrillation (%) 3 (9.6) 5 (16.1) 0.77 8 (12.9) 
AV block requiring temporary 
pace maker (%) 
3 (9.6) 4 (12.9) 1 7 (11.2) 
AV block requiring permanent 
pace -maker (%) 
1 (3.2) 0 1 1 (1.6) 
Post-operative MI (%) 0 0 - 0 
Reopening for bleeding (%) 0 1 (3.2) 1 1 (1.6) 
Stroke/TIA (%) 0 0 - 0 
Delirium (%) 1 (3.2) 0 1 1 (1.6) 
Pneumothorax or effusion 
requiring drain (%) 
1 (3.2) 2 (6.4) 1 3 (4.8) 
Wound dehiscence (%) 2 (6.4) 0 0.5 2 (3.2) 
Groin access complication (%) 1 (3.2) 1 (3.2) 1 2 (3.2) 
Values are presented as median (interquartile range), mean ± standard deviation, or n (%). AV, atrio-
ventricular. ICU, Intensive care unit. LOS, Length of stay. MI, Myocardial infarction. TIA, transient 
ischemic attack. 
 
